🎉 M&A multiples are live!
Check it out!

Madrigal Pharmaceuticals Valuation Multiples

Discover revenue and EBITDA valuation multiples for Madrigal Pharmaceuticals and similar public comparables like Pharming, Galapagos, and Benevolent AI.

Madrigal Pharmaceuticals Overview

About Madrigal Pharmaceuticals

Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, and premature mortality. The company's medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor agonist designed to target key underlying causes of MASH.


Founded

2011

HQ

United States of America
Employees

528

Financials

LTM Revenue $295M

LTM EBITDA -$478M

EV

$6.3B

Valuation Multiples

Multiples.vc

Sign up to see

Valuation Multiples for 10K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Madrigal Pharmaceuticals Financials

Madrigal Pharmaceuticals has a last 12-month revenue of $295M and a last 12-month EBITDA of -$478M.

In the most recent fiscal year, Madrigal Pharmaceuticals achieved revenue of $180M and an EBITDA of -$450M.

Madrigal Pharmaceuticals expects next 12-month revenue of  XXX    and NTM EBITDA of  XXX

See Madrigal Pharmaceuticals valuation multiples based on analyst estimates

Madrigal Pharmaceuticals P&L

FY 2023 FY 2024 FY 2025 LTM NTM
Revenue n/a $180M XXX XXX XXX
Gross Profit n/a n/a XXX XXX XXX
Gross Margin NaN% NaN% XXX XXX XXX
EBITDA -$360M -$450M XXX XXX XXX
EBITDA Margin -Infinity% -250% XXX XXX XXX
Net Profit -$295M -$374M XXX XXX XXX
Net Margin -Infinity% -207% XXX XXX XXX
Net Debt n/a $15.6M XXX XXX XXX

Financial data powered by Morningstar, Inc.

Madrigal Pharmaceuticals Stock Performance

As of April 15, 2025, Madrigal Pharmaceuticals's stock price is $322.

Madrigal Pharmaceuticals has current market cap of $7.1B, and EV of $6.3B.

See Madrigal Pharmaceuticals trading valuation data

Madrigal Pharmaceuticals Stock Data

EV Market Cap Price 1D Price 1M Price 3M Price 12M EPS
$6.3B $7.1B XXX XXX XXX XXX $-19.32

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Sign Up

Madrigal Pharmaceuticals Valuation Multiples

As of April 15, 2025, Madrigal Pharmaceuticals has market cap of $7.1B and EV of $6.3B.

Madrigal Pharmaceuticals's trades at 21.4x LTM EV/Revenue multiple, and -13.2x LTM EBITDA.

Analysts estimate Madrigal Pharmaceuticals's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See valuation multiples for Madrigal Pharmaceuticals and 10K+ public comps

Madrigal Pharmaceuticals Financial Valuation Multiples

FY 2024 FY 2025E FY 2026E FY 2027E
EV $6.3B XXX XXX XXX
EV/Revenue 35.0x XXX XXX XXX
EV/EBITDA -14.0x XXX XXX XXX
P/E -15.3x XXX XXX XXX
P/E/Growth n/a XXX XXX XXX
EV/FCF -13.7x XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Madrigal Pharmaceuticals Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Sign Up

Madrigal Pharmaceuticals Valuation Multiples

Madrigal Pharmaceuticals's NTM/LTM revenue growth is 142%

Madrigal Pharmaceuticals's revenue per employee for the last fiscal year averaged $0.3M, while opex per employee averaged $1.3M for the same period.

Over next 12 months, Madrigal Pharmaceuticals's ratio of sales and marketing spend to revenue is estimated to be  XXX , while its R&D spend to revenue to be  XXX .

Analysts estimate Madrigal Pharmaceuticals's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See operational valuation multiples for Madrigal Pharmaceuticals and other 10K+ public comps

Madrigal Pharmaceuticals Operational Valuation Multiples

FY 2024 NTM FY 2025E FY 2026E FY 2027E
Revenue Growth Infinity% XXX XXX XXX XXX
EBITDA Margin -250% XXX XXX XXX XXX
EBITDA Growth 25% XXX XXX XXX XXX
Rule of 40 (SaaS-only) -108% XXX XXX XXX XXX
Revenue per Employee $0.3M XXX XXX XXX XXX
Opex per Employee $1.3M XXX XXX XXX XXX
S&M Expenses to Revenue n/a XXX XXX XXX XXX
G&A Expenses to Revenue n/a XXX XXX XXX XXX
R&D Expenses to Revenue 131% XXX XXX XXX XXX
Opex to Revenue 373% XXX XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics
Pharma Analytics
Private Equity
ERP Software
Developer Tools
Consumer SaaS
Streaming Platforms

Madrigal Pharmaceuticals Public Comps

See public comps and valuation multiples for Drug Development & Therapeutics comps
EV/Revenue EV/EBITDA
2025E 2026E 2027E 2025E 2026E 2027E
Julphar XXX XXX XXX XXX XXX XXX
Benevolent AI XXX XXX XXX XXX XXX XXX
Galapagos XXX XXX XXX XXX XXX XXX
Pharming XXX XXX XXX XXX XXX XXX
Vivoryon Therapeutics XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX

Valuation data powered by FactSet, Inc.

Madrigal Pharmaceuticals M&A and Investment Activity

Madrigal Pharmaceuticals acquired  XXX companies to date.

Last acquisition by Madrigal Pharmaceuticals was  XXXXXXXX, XXXXX XXXXX XXXXXX . Madrigal Pharmaceuticals acquired  XXXXXXXX for  XXX (EV/Revenue multiple of  XXX ).

See M&A valuation multiples

Latest Acquisitions by Madrigal Pharmaceuticals

Acquired Company EV EV/Revenue EV/EBITDA
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX

Get Verified M&A Valuation Multiples

Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.

Sign Up

About Madrigal Pharmaceuticals

When was Madrigal Pharmaceuticals founded? Madrigal Pharmaceuticals was founded in 2011.
Where is Madrigal Pharmaceuticals headquartered? Madrigal Pharmaceuticals is headquartered in United States of America.
How many employees does Madrigal Pharmaceuticals have? As of today, Madrigal Pharmaceuticals has 528 employees.
Who is the CEO of Madrigal Pharmaceuticals? Madrigal Pharmaceuticals's CEO is Mr. William John (Bill) Sibold.
Is Madrigal Pharmaceuticals publicy listed? Yes, Madrigal Pharmaceuticals is a public company listed on NAS.
What is the stock symbol of Madrigal Pharmaceuticals? Madrigal Pharmaceuticals trades under MDGL ticker.
When did Madrigal Pharmaceuticals go public? Madrigal Pharmaceuticals went public in 2007.
Who are competitors of Madrigal Pharmaceuticals? Similar companies to Madrigal Pharmaceuticals include e.g. Julphar, Benevolent AI, Galapagos, Pharming.
What is the current market cap of Madrigal Pharmaceuticals? Madrigal Pharmaceuticals's current market cap is $7.1B
What is the current revenue of Madrigal Pharmaceuticals? Madrigal Pharmaceuticals's last 12-month revenue is $295M.
What is the current EBITDA of Madrigal Pharmaceuticals? Madrigal Pharmaceuticals's last 12-month EBITDA is -$478M.
What is the current EV/Revenue multiple of Madrigal Pharmaceuticals? Current revenue multiple of Madrigal Pharmaceuticals is 21.4x.
What is the current EV/EBITDA multiple of Madrigal Pharmaceuticals? Current EBITDA multiple of Madrigal Pharmaceuticals is -13.2x.
Is Madrigal Pharmaceuticals profitable? Yes, Madrigal Pharmaceuticals is EBITDA-positive (as of the last 12 months).

Join Now Or Talk To Us

Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.